https://scholars.lib.ntu.edu.tw/handle/123456789/638441
標題: | Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study | 作者: | Abdul Razak, Albiruni R Bauer, Sebastian Suarez, Cristina CHIA-CHI LIN Quek, Richard Hütter-Krönke, Marie Luise Cubedo, Ricardo Ferretti, Stephane Guerreiro, Nelson Jullion, Astrid Orlando, Elena J Clementi, Giorgia Sand Dejmek, Janna Halilovic, Ensar Fabre, Claire Blay, Jean-Yves Italiano, Antoine |
公開日期: | 15-三月-2022 | 卷: | 28 | 期: | 6 | 來源出版物: | Clinical cancer research : an official journal of the American Association for Cancer Research | 摘要: | Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are characterized by co-amplification of the murine double minute-2 (MDM2) and cyclin-dependent kinase-4 (CDK4) oncogenes. Siremadlin, a p53-MDM2 inhibitor, was combined with ribociclib, a CDK4/6 inhibitor, in patients with locally advanced/metastatic WDLPS or DDLPS who had radiologically progressed on, or despite, prior systemic therapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638441 | ISSN: | 10780432 | DOI: | 10.1158/1078-0432.CCR-21-1291 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。